Phibro Animal Health Corporation (PAHC), a leading manufacturer of animal health products and nutritional supplements, witnessed its stock soar 5.61% during Monday's trading session. This significant rise can be attributed to positive investor sentiment stemming from the company's robust international operations and potential undervaluation in the market.

According to a recent analysis, Phibro Animal Health's international revenue streams have exhibited promising growth trajectories. The company's reliance on foreign markets contributes to revenue diversification and exposure to faster-growing economies. Specifically, the Asia Pacific region contributed $19.56 million, or 6.32% of the total revenue, during the last fiscal quarter, marking a surprise of +7.72% compared to analysts' expectations.

Furthermore, valuation metrics suggest that Phibro Animal Health's stock may be currently undervalued by investors. The company's forward P/E ratio stands at an attractive 13.64, lower than the industry average of 22.57. Additionally, its P/B ratio of 3.85 and P/S ratio of 0.87 are favorable compared to industry peers, indicating potential for upside in the stock price.